Search 

Taifeng Group is a nationwide company, located in Henan province, focus on the medical industry in China. The company was established in 2005 and gradually formed a two-medicine model with both“Chinese and Western medicine research and development, manufacturing, and sales”. We developed a modern Taifeng Characteristic medicine system.

Focused in Chinese healthcare industry, with AUM over 11 billion RMB.

HitGen is a rapidly growing biotech company with headquarter and main research facility based in Chengdu, China and with a subsidiary in the United States. HitGen has established an industry-leading platform for early-stage drug discovery research centred on the design, synthesis and screening of DNA encoded chemical libraries (DELs).

HitGen’s DELs cover more than 500 billion novel, diverse molecules from different types of chemical libraries, including drug-like/lead-like small molecules, macrocycles, molecules with electrophiles (co-valent binding), protein degraders, molecular fragments, etc,. These compounds are members of DELs synthesized from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets.

In order to support the exploitation of DEL screening output, HitGen has also built structural biology, medicinal chemistry, in vitro and in vivo biology capabilities to support our partner’s drug discovery research projects.

HitGen is collaborating with pharmaceutical, biotech, and chemical companies, foundations and research institutes in North America, Europe, Asia and Africa to discover and develop approaches for novel medicines and other solutions.

HitGen's novel small molecule inhibitor for Class I/IIb HDAC, HG146, is in Phase I clinical trials for Multiple Myeloma. Another new class of second generation TRK/ROS1 inhibitor, HG030, has obtained clinical approval from NMPA. HitGen’s preclinical portfolio includes small molecule IL17A inhibitor and non-nucleoside STING agonist.

http://chinabio-partnering.com/events/CBPF2020/en/home

focus on biotech,IVD

Hong Kong Biotechnology Organization is an independent nonprofit organization with the goal to promote best practice, raise awareness across the biotechnology industry while providing added value benefits to its members, whether they are students, researchers, entrepreneurs, industry bodies, public or private sector representatives.

Founded by pioneering scientists with extensive life science backgrounds and multi-cultural experience in research and development, engineering and business. Hong Kong Biotechnology Organization aims to establish and facilitate a worldwide platform for the Hong Kong biotech industry, promote awareness, encouraging and enabling international collaboration. We also provide informed opinion and technical advice to government bodies, healthcare institutions and the general public.

· About Us
Chairman，Mr. Rongguang WU is also the founder of Hongxing Erke , which is one of the most famous sports brands in China. We focus on investing in innovative biotech companies and healthcare funds worldwide. We have an expert team and also seek license-in opportunity of innovative drugs to develop and commercialize in China.

· Investment Cases

Previously, we've invested over 100 million dollars, more than 10 projects worldwide, including VIR Biotechnology, Beijing Genomics institution, GMAX Bio and two Top 10 biomedical funds in America, etc..

· Investment Preference

We don’t have clear limits on the investment scale and the proportion of shares, usually $5 million to $20 million of a single investment. Companies in initial stage to growth stage are all in our consideration. We can lead, co-lead, or join a round that others are leading.

Website：www.hongxingerke.com

PE/VC firm

Huahai Investment Co, Ltd is a young, China-based firm backed by the Huahai Pharmaceuticals Group, a listed company in the Shanghai Stock Exchange. Our twin missions are to make investment as well as partnership deals in the healthcare sector.

Investnwnt business focus on start company of BT

equity investment